Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Biochemistry of prostate specific antigen, PSA

Malm, J. LU and Lilja, H. LU orcid (1995) In Scandinavian Journal of Clinical and Laboratory Investigation 55(S221). p.15-22
Abstract

Human prostate specific antigen, PSA, is a product of the human glandular kallikrein gene locus on chromosome 19 that is almost selectively expressed by prostate tissue. PSA is one of the dominating prostate derived proteins in seminal fluid. The mature form of PSA, a single chain glycoprotein of 237 amino acids, is a serine protease manifesting restricted chymotrypsin-like activity. PSA is mainly responsible for gel dissolution in freshly ejaculated semen by proteolysis of the major gel forming proteins, semenogelin I and II, and fibronectin. In semen approximately two thirds of PSA is enzymatically active. The remaining 30 - 40% is inactive due to internal cleavage(s). A few per cent of PSA in semen is complexed to the protein C... (More)

Human prostate specific antigen, PSA, is a product of the human glandular kallikrein gene locus on chromosome 19 that is almost selectively expressed by prostate tissue. PSA is one of the dominating prostate derived proteins in seminal fluid. The mature form of PSA, a single chain glycoprotein of 237 amino acids, is a serine protease manifesting restricted chymotrypsin-like activity. PSA is mainly responsible for gel dissolution in freshly ejaculated semen by proteolysis of the major gel forming proteins, semenogelin I and II, and fibronectin. In semen approximately two thirds of PSA is enzymatically active. The remaining 30 - 40% is inactive due to internal cleavage(s). A few per cent of PSA in semen is complexed to the protein C inhibitor. PSA complexed to α1-antichymotrypsin (ACT) constitutes the predominant molecular form of serum PSA, although complex formation is slow between the purified proteins in vitro. PSA also forms stable complexes with α2-macroglobulin in vitro but as this results in encapsulation of PSA and complete loss of the PSA-epitopes, the in vivo significance of this complex formation is presently unclear. A free, non-complexed form of PSA constitutes a minor fraction of the serum PSA despite the large molar excess of antiproteasees such as ACT. In patients with carcinoma of the prostate the serum PSA level increases. Analysis of the serum level of PSA is used both for diagnosing and monitoring patients with carcinoma of the prostate (CAP). These can now more efficiently be distinguished from subjects with benign hyperplasia of the prostate (BPH) alone, who often also have increased concentrations of PSA in serum, by specific measurements of the individual forms of PSA in serum. Patients with CAP have a higher ratio of PSA-ACT complexes to total PSA in serum than BPH subjects and a lower ratio of free to total PSA.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Clinical and Laboratory Investigation
volume
55
issue
S221
pages
15 - 22
publisher
Informa Healthcare
external identifiers
  • scopus:0028936865
  • pmid:7544481
ISSN
0036-5513
DOI
10.3109/00365519509090559
language
English
LU publication?
yes
additional info
Funding Information: Our thanks are due to Birgitta Frohm, BSc, Ingrid Wigheden, Gun-Britt Eriksson, and professor emeritus Carl-Bertil Laurell. This investigation was supported by the Swedish Research Council (grant no. B93-13X-7903-07A), the Faculty of Medicine at Lund University, the Research Fund and the Cancer Research Fund at Malmo General Hospital, the Magnus Bergvall Foundation, the Cra-foord Foundation, the Sven-Erik and Anna-Lisa Lundgren Foundation, the Agnes and Nils Nilsson Foundation, the John and Augusta Persson Foundation, Syskonen Svenssons Foundation, the Alfred Osterlund Foundation, the Fundacion Federico S.A.
id
df3fd4cd-a74c-4eda-b6f0-8d5d16647f9a
date added to LUP
2022-12-08 13:14:36
date last changed
2024-01-02 13:55:51
@article{df3fd4cd-a74c-4eda-b6f0-8d5d16647f9a,
  abstract     = {{<p>Human prostate specific antigen, PSA, is a product of the human glandular kallikrein gene locus on chromosome 19 that is almost selectively expressed by prostate tissue. PSA is one of the dominating prostate derived proteins in seminal fluid. The mature form of PSA, a single chain glycoprotein of 237 amino acids, is a serine protease manifesting restricted chymotrypsin-like activity. PSA is mainly responsible for gel dissolution in freshly ejaculated semen by proteolysis of the major gel forming proteins, semenogelin I and II, and fibronectin. In semen approximately two thirds of PSA is enzymatically active. The remaining 30 - 40% is inactive due to internal cleavage(s). A few per cent of PSA in semen is complexed to the protein C inhibitor. PSA complexed to α1-antichymotrypsin (ACT) constitutes the predominant molecular form of serum PSA, although complex formation is slow between the purified proteins in vitro. PSA also forms stable complexes with α2-macroglobulin in vitro but as this results in encapsulation of PSA and complete loss of the PSA-epitopes, the in vivo significance of this complex formation is presently unclear. A free, non-complexed form of PSA constitutes a minor fraction of the serum PSA despite the large molar excess of antiproteasees such as ACT. In patients with carcinoma of the prostate the serum PSA level increases. Analysis of the serum level of PSA is used both for diagnosing and monitoring patients with carcinoma of the prostate (CAP). These can now more efficiently be distinguished from subjects with benign hyperplasia of the prostate (BPH) alone, who often also have increased concentrations of PSA in serum, by specific measurements of the individual forms of PSA in serum. Patients with CAP have a higher ratio of PSA-ACT complexes to total PSA in serum than BPH subjects and a lower ratio of free to total PSA.</p>}},
  author       = {{Malm, J. and Lilja, H.}},
  issn         = {{0036-5513}},
  language     = {{eng}},
  number       = {{S221}},
  pages        = {{15--22}},
  publisher    = {{Informa Healthcare}},
  series       = {{Scandinavian Journal of Clinical and Laboratory Investigation}},
  title        = {{Biochemistry of prostate specific antigen, PSA}},
  url          = {{http://dx.doi.org/10.3109/00365519509090559}},
  doi          = {{10.3109/00365519509090559}},
  volume       = {{55}},
  year         = {{1995}},
}